Cagrilintide

Cagrilintide (Long-Acting Amylin Analogue — AM833)

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

A long-acting amylin receptor agonist in late-stage clinical development, studied primarily in combination with Semaglutide for obesity and type 2 diabetes. Designed to complement GLP-1 receptor agonism through a distinct but synergistic mechanism.

Plain English

Researchers study Cagrilintide because it activates the amylin receptor with a once-weekly duration well suited for combination with Semaglutide. Scientists are interested in whether combining GLP-1 receptor agonism with amylin receptor activation produces additive benefits on weight loss and glucose control. The combination — called CagriSema — is in Phase III trials and is being closely followed as a potential next stage in the development of combination metabolic pharmacotherapy.

Overview

Cagrilintide is an investigational long-acting amylin analogue. Evidence for cagrilintide monotherapy must remain distinct from evidence for the fixed-dose cagrilintide/semaglutide combination, CagriSema. Neither cagrilintide nor CagriSema is FDA-approved, and trial dose-escalation schedules are not recommendations for clinical use.

Research Summary

A randomized cagrilintide monotherapy study reported weight-loss findings in adults with overweight or obesity. Separate Phase III publications report results for the cagrilintide/semaglutide combination CagriSema in obesity and type 2 diabetes populations. These outcomes must not be attributed to cagrilintide monotherapy, and neither product is FDA-approved.

Research Areas

  • Cagrilintide monotherapy weight-management research
  • CagriSema combination research

Safety & Risks

Serious Risks

  • Thyroid-related safety remains under investigation; a cagrilintide-specific human thyroid C-cell risk has not been established. Established thyroid C-cell tumor warnings for semaglutide-containing products are not attributed here to cagrilintide.
  • Pancreatitis remains an unresolved safety question; a cagrilintide-specific human risk has not been established in this record.

Reported Side Effects

  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • Injection site reactions
United States
Investigational; not FDA-approved
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources